Chapter 10 : Antiviral Targets in Orthopoxviruses

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in

Antiviral Targets in Orthopoxviruses, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815493/9781555814397_Chap10-1.gif /docserver/preview/fulltext/10.1128/9781555815493/9781555814397_Chap10-2.gif


This chapter summarizes many targets for orthopoxviruses that might be exploited in the discovery of additional agents for potential diseases and indicates the mechanisms of action of a number of compounds. The viral DNA polymerase performs a critical role in viral replication, and its susceptibility to nucleoside analogs has made it the dominant target for the development of antiviral drugs. The synthesis of deoxynucleotides is also catalyzed by the heterodimeric ribonucleotide reductase encoded by F4L and I4L. Ribonucleotide reductase converts ribonucleotides to the corresponding deoxyribonucleotides at the level of the diphosphate and supplies deoxyribonucleoside triphosphates to support DNA replication in the cytoplasm. A number of small molecules are known to broadly target protein kinases, and it is possible that medicinal chemistry efforts could identify selective inhibitors. Immature virions containing genomic DNA undergo complex maturation that leads to the condensation of virus cores and involves proteolytic events, the loss of D13, and the formation of new disulfide linkage catalyzed by the viral redox system. The complex replication cycle of the orthopoxviruses requires the concerted activities of numerous viral proteins. The chapter also summarizes each of the stages of viral replication, notes the viral proteins that perform critical functions, and identifies specific inhibitors that affect these processes.

Citation: Prichard M, Kern E. 2009. Antiviral Targets in Orthopoxviruses, p 167-186. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch10

Key Concept Ranking

Viral Life Cycle
Vaccinia virus
Variola virus
Monkeypox virus
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


1. Adams, M. M.,, A. D. Rice, and, R. W. Moyer. 2007. Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox.J. Virol. 81:1108411095.
2. Ahn, B. Y.,, P. D. Gershon, and, B. Moss. 1994. RNA polymerase-associated protein Rap94 confers promoter specificity for initiating transcription of vaccinia virus early stage genes. J. Biol. Chem.269:75527557.
3. Aldaz-Carroll, L.,, J. C. Whitbeck,, M. Ponce de Leon,, H. Lou,, L. Hirao,, S. N. Isaacs,, B. Moss,, R. J. Eisenberg, and, G. H. Cohen. 2005. Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J. Virol.79:62606271.
4. Aldaz-Carroll, L.,, Y. Xiao,, J. C. Whitbeck,, M. Ponce de Leon,, H. Lou,, M. Kim,, J. Yu,, E. L. Reinherz,, S. N. Isaacs,, R. J. Eisenberg, and, G. H. Cohen. 2007. Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6.J. Virol. 81:81318139.
5. Aldern, K. A.,, S. L. Ciesla,, K. L. Winegarden, and, K. Y. Hostetler. 2003. Increased antiviral activity of 1-O-hexadecyloxypropyl-(2-14C)cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol. Pharmacol.63:678681.
6. Andrei, G.,, D. B. Gammon,, P. Fiten,, E. De Clercq,, G. Opdenakker,, R. Snoeck, and, D. H. Evans. 2006. Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J. Virol.80:93919401.
7. Ansarah-Sobrinho, C., and, B. Moss. 2004. Vaccinia virus G1 protein, a predicted metalloprotease, is essential for morphogenesis of infectious virions but not for cleavage of major core proteins. J. Virol.78:68556863.
8. Baker, R. O.,, M. Bray, and, J. W. Huggins. 2003. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antivir. Res.57:1323.
9. Baldick, C. J., Jr., and, B. Moss. 1987. Resistance of vaccinia virus to rifampicin conferred by a single nucleotide substitution near the predicted NH2 terminus of a gene encoding an Mr 62,000 polypeptide.Virology 156:138145.
10. Banham, A. H., and, G. L. Smith. 1992. Vaccinia virus gene B1R encodes a 34-kDa serine/threonine protein kinase that localizes in cytoplasmic factories and is packaged into virions. Virology191:803812.
11. Barbosa, E., and, B. Moss. 1978. mRNA(nucleoside-2’-)-methyltransferase from vaccinia virus. Characteristics and substrate specificity. J. Biol. Chem.253:76987702.
12. Baroudy, B. M., and, B. Moss. 1980. Purification and characterization of a DNA-dependent RNA polymerase from vaccinia virions.J. Biol. Chem. 255:43724380.
13. Baroudy, B. M.,, S. Venkatesan, and, B. Moss. 1982. Incompletely base-paired flip-flop terminal loops link the two DNA strands of the vaccinia virus genome into one uninterrupted polynucleotide chain.Cell 28:315324.
14. Bauer, D. J. 1955. The antiviral and synergic actions of isatin thiosemicarbazone and certain phenoxypyrimidines in vaccinia infection in mice. Br. J. Exp. Pathol.36:105114.
15. Bayliss, C. D., and, R. C. Condit. 1993. Temperature-sensitive mutants in the vaccinia virus A18R gene increase double-stranded RNA synthesis as a result of aberrant viral transcription. Virology194:254262.
16. Bayliss, C. D., and, R. C. Condit. 1995. The vaccinia virus A18R gene product is a DNA-dependent ATPase. J. Biol. Chem.270:15501556.
17. Beadle, J. R.,, W. B. Wan,, S. L. Ciesla,, K. A. Keith,, C. Hartline,, E. R. Kern, and, K. Y. Hostetler. 2006. Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses. J. Med. Chem.49:20102015.
18. Beaud, G. 1995. Vaccinia virus DNA replication: a short review. Biochimie77:774779.
19. Beaud, G.,, R. Beaud, and, D. P. Leader. 1995. Vaccinia virus gene H5R encodes a protein that is phosphorylated by the multi-substrate vaccinia virus B1R protein kinase. J. Virol. 69:18191826.
20. Bell, E.,, M. Shamim,, J. C. Whitbeck,, G. Sfyroera,, J. D. Lambris, and, S. N. Isaacs. 2004. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology325:425431.
21. Betakova, T.,, E. J. Wolffe, and, B. Moss. 1999. Regulation of vaccinia virus morphogenesis: phosphorylation of the A14L and A17L membrane proteins and C-terminal truncation of the A17L protein are dependent on the F10L kinase. J. Virol.73:35343543.
22. Biron, K. K.,, R. J. Harvey,, S. C. Chamberlain,, S. S. Good,, A. A. Smith III,, M. G. Davis,, C. L. Talarico,, W. H. Miller,, R. Ferris,, R. E. Dornsife,, S. C. Stanat,, J. C. Drach,, L. B. Townsend, and, G. W. Koszalka. 2002. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action. Antimicrob. Agents Chemother.46:23652372.
23. Black, E. P., and, R. C. Condit. 1996. Phenotypic characterization of mutants in vaccinia virus gene G2R, a putative transcription elongation factor. J. Virol.70:4754.
24. Black, M. E., and, D. E. Hruby. 1992. A single amino acid substitution abolishes feedback inhibition of vaccinia virus thymidine kinase.J. Biol. Chem. 267:97439748.
25. Black, M. E., and, D. E. Hruby. 1992. Site-directed mutagenesis of a conserved domain in vaccinia virus thymidine kinase. Evidence for a potential role in magnesium binding. J. Biol. Chem.267:68016806.
26. Blasco, R.,, N. B. Cole, and, B. Moss. 1991. Sequence analysis, expression, and deletion of a vaccinia virus gene encoding a homolog of profilin, a eukaryotic actin-binding protein. J. Virol.65:45984608.
27. Blasco, R.,, J. R. Sisler, and, B. Moss. 1993. Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene. J. Virol.67:33193325.
28. Bond, A.,, Z. Reichert, and, J. T. Stivers. 2006. Novel and specific inhibitors of a poxvirus type I topoisomerase. Mol. Pharmacol.69:547557.
29. Bougie, I., and, M. Bisaillon. 2004. The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme.J. Biol. Chem. 279:2212422130.
30. Boyle, K. A.,, L. Arps, and, P. Traktman. 2007. Biochemical and genetic analysis of the vaccinia virus d5 protein: multimerization-dependent ATPase activity is required to support viral DNA replication.J. Virol. 81:844859.
31. Bray, M.,, M. Martinez,, D. F. Smee,, D. Kefauver,, E. Thompson, and, J. W. Huggins. 2000. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 181:1019.
32. Bray, M., and, M. E. Wright. 2003. Progressive vaccinia. Clin. Infect. Dis.36:766774.
33. Breman, J. G., and, D. A. Henderson. 1998. Poxvirus dilemmas— monkeypox, smallpox, and biologic terrorism. N. Engl. J. Med.339:556559.
34. Brown, E.,, T. G. Senkevich, and, B. Moss. 2006. Vaccinia virus F9 virion membrane protein is required for entry but not virus assembly, in contrast to the related L1 protein. J. Virol. 80:94559464.
35. Brown, N. G.,, D. Nick Morrice,, G. Beaud,, G. Hardie, and, D. P. Leader. 2000. Identification of sites phosphorylated by the vaccinia virus B1R kinase in viral protein H5R. BMC Biochem.1:2.
36. Broyles, S. S. 2003. Vaccinia virus transcription. J. Gen. Virol.84:22932303.
37. Broyles, S. S.,, X. Liu,, M. Zhu, and, M. Kremer. 1999. Transcription factor YY1 is a vaccinia virus late promoter activator. J. Biol. Chem.274:3566235667.
38. Buerger, I.,, J. Reefschlaeger,, W. Bender,, P. Eckenberg,, A. Popp,, O. Weber,, S. Graeper,, H. D. Klenk,, H. Ruebsamen-Waigmann, and, S. Hallenberger. 2001. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J. Virol.75:90779086.
39. Buller, R. M.,, G. Owens,, J. Schriewer,, L. Melman,, J. R. Beadle, and, K. Y. Hostetler. 2004. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 318:474481.
40. Byrd, C. M.,, T. C. Bolken, and, D. E. Hruby. 2002. The vaccinia virus I7L gene product is the core protein proteinase. J. Virol.76:89738976.
41. Byrd, C. M.,, T. C. Bolken,, A. M. Mjalli,, M. N. Arimilli,, R. C. Andrews,, R. Rothlein,, T. Andrea,, M. Rao,, K. L. Owens, and, D. E. Hruby. 2004. New class of orthopoxvirus antiviral drugs that block viral maturation. J. Virol.78:1214712156.
42. Byrd, C. M., and, D. E. Hruby. 2006. Vaccinia virus proteolysis— a review. Rev. Med. Virol.16:187202.
43. Carter, G. C.,, M. Law,, M. Hollinshead, and, G. L. Smith. 2005. Entry of the vaccinia virus intracellular mature virion and its interactions with glycosaminoglycans. J. Gen. Virol. 86:12791290.
44. Carter, G. C.,, G. Rodger,, B. J. Murphy,, M. Law,, O. Krauss,, M. Hollinshead, and, G. L. Smith. 2003. Vaccinia virus cores are transported on microtubules. J. Gen. Virol.84:24432458.
45. Cassetti, M. C.,, M. Merchlinsky,, E. J. Wolffe,, A. S. Weisberg, and, B. Moss. 1998. DNA packaging mutant: repression of the vaccinia virus A32 gene results in noninfectious, DNA-deficient, spherical, enveloped particles. J. Virol.72:57695780.
46. Centers for Disease Control and Prevention. 2003. Multistate outbreak of monkeypox—Illinois, Indiana, and Wisconsin, 2003. Morb. Mortal. Wkly. Rep.52:537540.
47. Charity, J. C.,, E. Katz, and, B. Moss. 2007. Amino acid substitutions at multiple sites within the vaccinia virus D13 scaffold protein confer resistance to rifampicin. Virology359:227232.
48. Chen, N.,, G. Li,, M. K. Liszewski,, J. P. Atkinson,, P. B. Jahrling,, Z. Feng,, J. Schriewer,, C. Buck,, C. Wang,, E. J. Lefkowitz,, J. J. Esposito,, T. Harms,, I. K. Damon,, R. L. Roper,, C. Upton, and, R. M. Buller. 2005. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology340:4663.
49. Child, S. J.,, G. J. Palumbo,, R. M. Buller, and, D. E. Hruby. 1990. Insertional inactivation of the large subunit of ribonucleotide reductase encoded by vaccinia virus is associated with reduced virulence in vivo. Virology174:625629.
50. Chiu, W. L.,, C. L. Lin,, M. H. Yang,, D. L. Tzou, and, W. Chang. 2007. Vaccinia virus 4c (A26L) protein on intracellular mature virus binds to the extracellular cellular matrix laminin. J. Virol.81:21492157.
51. Ciesla, S. L.,, J. Trahan,, W. B. Wan,, J. R. Beadle,, K. A. Aldern,, G. R. Painter, and, K. Y. Hostetler. 2003. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antivir. Res.59:163171.
52. Colinas, R. J.,, S. J. Goebel,, S. W. Davis,, G. P. Johnson,, E. K. Norton, and, E. Paoletti. 1990. A DNA ligase gene in the Copenhagen strain of vaccinia virus is nonessential for viral replication and recombination.Virology 179:267275.
53. Condit, R. C.,, R. Easterly,, R. F. Pacha,, Z. Fathi, and, R. J. Meis. 1991. A vaccinia virus isatin-beta-thiosemicarbazone resistance mutation maps in the viral gene encoding the 132-kDa subunit of RNA polymerase. Virology185:857861.
54. Condit, R. C.,, N. Moussatche, and, P. Traktman. 2006. In a nutshell: structure and assembly of the vaccinia virion. Adv. Virus Res.66:31124.
55. Condit, R. C., and, E. G. Niles. 2002. Regulation of viral transcription elongation and termination during vaccinia virus infection.Biochim. Biophys. Acta 1577:325336.
56. Condit, R. C.,, Y. Xiang, and, J. I. Lewis. 1996. Mutation of vaccinia virus gene G2R causes suppression of gene A18R ts mutants: implications for control of transcription. Virology 220:1019.
57. Cresawn, S. G., and, R. C. Condit. 2007. A targeted approach to identification of vaccinia virus postreplicative transcription elongation factors: genetic evidence for a role of the H5R gene in vaccinia transcription. Virology363:333341.
58. Cundy, K. C.,, A. M. Bidgood,, G. Lynch,, J. P. Shaw,, L. Griffin, and, W. A. Lee. 1996. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab. Dispos.24:745752.
59. Da Fonseca, F., and, B. Moss. 2003. Poxvirus DNA topoisomerase knockout mutant exhibits decreased infectivity associated with reduced early transcription. Proc. Natl. Acad. Sci. USA 100:1129111296.
60. da Fonseca, F. G.,, A. S. Weisberg,, M. F. Caeiro, and, B. Moss. 2004. Vaccinia virus mutants with alanine substitutions in the conserved G5R gene fail to initiate morphogenesis at the nonper-missive temperature. J. Virol.78:1023810248.
61. da Fonseca, F. G.,, E. J. Wolffe,, A. Weisberg, and, B. Moss. 2000. Effects of deletion or stringent repression of the H3L envelope gene on vaccinia virus replication. J. Virol.74:75187528.
62. Da Silva, M., and, C. Upton. 2005. Using purine skews to predict genes in AT-rich poxviruses. BMC Genomics6:22.
63. De Clercq, E. 2002. Cidofovir in the treatment of poxvirus infections.Antivir. Res. 55:113.
64. De Clercq, E. 2005. John Montgomery’s legacy: carbocyclic adenosine analogues as SAH hydrolase inhibitors with broad-spectrum antiviral activity. Nucleosides Nucleotides Nucleic Acids 24:1395415.
65. De Clercq, E. 2001. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin. Microbiol. Rev.14:382397.
66. De Clercq, E.,, G. Andrei,, J. Balzarini,, P. Leyssen,, L. Naesens,, J. Neyts,, C. Pannecouque,, R. Snoeck,, C. Ying,, D. Hockova, and, A. Holy. 2005. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-(2-(phosphonomethoxy)alkoxy)-2,4-diaminopyrimidines. Nucleosides Nucleotides Nucleic Acids 24:331341.
67. De Clercq, E., and, P. De Somer. 1968. Effect of interferon, poly-acrylic acid, and polymethacrylic acid on tail lesions on mice infected with vaccinia virus. Appl. Microbiol.16:13141319.
68. De Clercq, E.,, A. Holy, and, I. Rosenberg. 1989. Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. Antimicrob. Agents Chemother.33:185191.
69. De Clercq, E.,, M. Luczak,, D. Shugar,, P. F. Torrence,, J. A. Waters, and, B. Witkop. 1976. Effect of cytosine, arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus. Proc. Soc. Exp. Biol. Med. 151:487490.
70. De Clercq, E., and, J. Neyts. 2004. Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections. Rev. Med. Virol.14:289300.
71. De Clercq, E.,, T. Sakuma,, M. Baba,, R. Pauwels,, J. Balzarini,, I. Rosenberg, and, A. Holy. 1987. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antivir. Res.8:261272.
72. DeMasi, J.,, S. Du,, D. Lennon, and, P. Traktman. 2001. Vaccinia virus telomeres: interaction with the viral I1, I6, and K4 proteins. J. Virol.75:1009010105.
73. Deng, L., and, S. Shuman. 1998. Vaccinia NPH-I, a DExH-box ATPase, is the energy coupling factor for mRNA transcription termination.Genes Dev. 12:538546.
74. Derrien, M.,, A. Punjabi,, M. Khanna,, O. Grubisha, and, P. Traktman. 1999. Tyrosine phosphorylation of A17 during vaccinia virus infection: involvement of the H1 phosphatase and the F10 kinase.J. Virol. 73:72877296.
75. De Silva, F. S., and, B. Moss. 2003. Vaccinia virus uracil DNA glycosylase has an essential role in DNA synthesis that is independent of its glycosylase activity: catalytic site mutations reduce virulence but not virus replication in cultured cells. J. Virol.77:159166.
76. Domi, A., and, G. Beaud. 2000. The punctate sites of accumulation of vaccinia virus early proteins are precursors of sites of viral DNA synthesis. J. Gen. Virol.81:12311235.
77. Doms, R. W.,, R. Blumenthal, and, B. Moss. 1990. Fusion of intraand extracellular forms of vaccinia virus with the cell membrane. J. Virol.64:48844892.
78. Duraffour, S.,, R. Snoeck,, R. de Vos,, J. J. van Den Oord,, J. M. Crance,, D. Garin,, D. E. Hruby,, R. Jordan,, E. De Clercq, and, G. Andrei. 2007. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir. Ther.12:12051216.
79. Eckert, D.,, O. Williams,, C. A. Meseda, and, M. Merchlinsky. 2005. Vaccinia virus nicking-joining enzyme is encoded by K4L (VACWR035). J. Virol.79:1508415090.
80. El Omari, K.,, N. Solaroli,, A. Karlsson,, J. Balzarini, and, D. K. Stammers. 2006. Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design. BMC Struct. Biol.6:22.
81. Engelstad, M., and, G. L. Smith. 1993. The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence. Virology 194:627637.
82. Esposito, J., and, F. Fenner. 2001. Poxviruses, p. 3087. In B. N. Fields,, D. M. Knipe,, P. M. Howley, and, D. E. Griffin (ed.), Fields Virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
83. Evans, E., and, P. Traktman. 1992. Characterization of vaccinia virus DNA replication mutants with lesions in the D5 gene. Chromosoma102:S72S82.
84. Fan, X.,, X. Zhang,, L. Zhou,, K. A. Keith,, M. N. Prichard,, E. R. Kern, and, P. F. Torrence. 2006. Toward orthopoxvirus countermeasures: a novel heteromorphic nucleoside of unusual structure. J. Med. Chem.49:40524054.
85. Franke, C. A.,, C. M. Rice,, J. H. Strauss, and, D. E. Hruby. 1985. Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia virus recombinants. Mol. Cell. Biol.5:19181924.
86. Frischknecht, F.,, V. Moreau,, S. Rottger,, S. Gonfloni,, I. Reckmann,, G. Superti-Furga, and, M. Way. 1999. Actin-based motility of vaccinia virus mimics receptor tyrosine kinase signalling. Nature401:926929.
87. Galmiche, M. C.,, J. Goenaga,, R. Wittek, and, L. Rindisbacher. 1999. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology254:7180.
88. Garcia, A. D., and, B. Moss. 2001. Repression of vaccinia virus Holliday junction resolvase inhibits processing of viral DNA into unit-length genomes. J. Virol.75:64606471.
89. Garcia, A. D.,, J. Otero,, J. Lebowitz,, P. Schuck, and, B. Moss. 2006. Quaternary structure and cleavage specificity of a poxvirus holliday junction resolvase. J. Biol. Chem.281:1161811626.
90. Gershon, P. D.,, B. Y. Ahn,, M. Garfield, and, B. Moss. 1991. Poly(A) polymerase and a dissociable polyadenylation stimulatory factor encoded by vaccinia virus. Cell66:12691278.
91. Gershon, P. D., and, B. Moss. 1990. Early transcription factor subunits are encoded by vaccinia virus late genes. Proc. Natl. Acad. Sci. USA87:44014405.
92. Gershon, P. D., and, B. Moss. 1993. Stimulation of poly(A) tail elongation by the VP39 subunit of the vaccinia virus-encoded poly(A) polymerase. J. Biol. Chem.268:22032210.
93. Goebel, S. J.,, G. P. Johnson,, M. E. Perkus,, S. W. Davis,, J. P. Winslow, and, E. Paoletti. 1990. The complete DNA sequence of vaccinia virus. Virology179:247266, 517563.
94. Greenberg, M.,, N. Cammack,, M. Salgo, and, L. Smiley. 2004. HIV fusion and its inhibition in antiretroviral therapy. Rev. Med. Virol.14:321337.
95. Grimley, P. M.,, E. N. Rosenblum,, S. J. Mims, and, B. Moss. 1970. Interruption by Rifampin of an early stage in vaccinia virus morphogenesis: accumulation of membranes which are precursors of virus envelopes. J. Virol.6:519533.
96. Grosenbach, D. W.,, D. O. Ulaeto, and, D. E. Hruby. 1997. Palmitylation of the vaccinia virus 37-kDa major envelope antigen. Identification of a conserved acceptor motif and biological relevance.J. Biol. Chem. 272:19561964.
97. Grubisha, O., and, P. Traktman. 2003. Genetic analysis of the vaccinia virus I6 telomere-binding protein uncovers a key role in genome encapsidation. J. Virol.77:1092910942.
98. Guan, K.,, D. J. Hakes,, Y. Wang,, H. D. Park,, T. G. Cooper, and, J. E. Dixon. 1992. A yeast protein phosphatase related to the vaccinia virus VH1 phosphatase is induced by nitrogen starvation.Proc. Natl. Acad. Sci. USA 89:1217512179.
99. Hakes, D. J.,, K. J. Martell,, W. G. Zhao,, R. F. Massung,, J. J. Esposito, and, J. E. Dixon. 1993. A protein phosphatase related to the vaccinia virus VH1 is encoded in the genomes of several orthopoxviruses and a baculovirus. Proc. Natl. Acad. Sci. USA90:40174021.
100. Hamilton, M. D.,, A. A. Nuara,, D. B. Gammon,, R. M. Buller, and, D. H. Evans. 2007. Duplex strand joining reactions catalyzed by vaccinia virus DNA polymerase. Nucleic Acids Res.35:143151.
101. Henderson, D. A. 1998. Bioterrorism as a public health threat. Emerg. Infect. Dis.4:488492.
102. Heymann, D. L.,, M. Szczeniowski, and, K. Esteves. 1998. Re-emergence of monkeypox in Africa: a review of the past six years.Br. Med. Bull. 54:693702.
103. Hiller, G.,, H. Eibl, and, K. Weber. 1981. Characterization of intracellular and extracellular vaccinia virus variants: N1-isonicotinoyl-N2-3-methyl-4-chlorobenzoylhydrazine interferes with cytoplasmic virus dissemination and release. J. Virol.39:903913.
104. Honeychurch, K. M.,, G. Yang,, R. Jordan, and, D. E. Hruby. 2007. The vaccinia virus F13L YPPL motif is required for efficient release of extracellular enveloped virus. J. Virol.81:73107315.
105. Hruby, D. E. 1985. Inhibition of vaccinia virus thymidine kinase by the distal products of its own metabolic pathway. Virus Res.2:151156.
106. Hruby, D. E.,, R. A. Maki,, D. B. Miller, and, L. A. Ball. 1983. Fine structure analysis and nucleotide sequence of the vaccinia virus thymidine kinase gene. Proc. Natl. Acad. Sci. USA80:34113415.
107. Hruby, D. E.,, D. B. Miller, and, L. A. Ball. 1982. Synthesis of vaccinia virus thymidine kinase in microinjected Xenopus oocytes. Virology 123:470473.
108. Hughes, S. J.,, L. H. Johnston,, A. de Carlos, and, G. L. Smith. 1991. Vaccinia virus encodes an active thymidylate kinase that complements a cdc8 mutant of Saccharomyces cerevisiae. J. Biol. Chem. 266:2010320109.
109. Husain, M., and, B. Moss. 2003. Intracellular trafficking of a palmitoylated membrane-associated protein component of enveloped vaccinia virus. J. Virol.77:90089019.
110. Husain, M., and, B. Moss. 2002. Similarities in the induction of post-Golgi vesicles by the vaccinia virus F13L protein and phospholipase D. J. Virol.76:77777789.
111. Hutin, Y. J.,, R. J. Williams,, P. Malfait,, R. Pebody,, V. N. Loparev,, S. L. Ropp,, M. Rodriguez,, J. C. Knight,, F. K. Tshioko,, A. S. Khan,, M. V. Szczeniowski, and, J. J. Esposito. 2001. Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997.Emerg. Infect. Dis. 7:434438.
112. Ichihashi, Y., and, M. Oie. 1996. Neutralizing epitope on penetration protein of vaccinia virus. Virology220:491494.
113. Ikeda, S.,, M. Yazawa, and, C. Nishimura. 1987. Antiviral activity and inhibition of topoisomerase by ofloxacin, a new quino-lone derivative. Antivir. Res.8:103113.
114. Ishii, K., and, B. Moss. 2002. Mapping interaction sites of the A20R protein component of the vaccinia virus DNA replication complex.Virology 303:232239.
115. Ishii, K., and, B. Moss. 2001. Role of vaccinia virus A20R protein in DNA replication: construction and characterization of temperature-sensitive mutants. J. Virol.75:16561663.
116. Kamau, E., and, A. Grove. 2004. Fluoroquinolone-dependent DNA supercoiling by Vaccinia topoisomerase I. J. Mol. Biol.342:479487.
117. Kane, E. M., and, S. Shuman. 1995. Adenosine N1-oxide inhibits vaccinia virus replication by blocking translation of viral early mRNAs.J. Virol. 69:63526358.
118. Kane, E. M., and, S. Shuman. 1992. Temperature-sensitive mutations in the vaccinia virus H4 gene encoding a component of the virion RNA polymerase. J. Virol.66:57525762.
119. Kato, N.,, H. J. Eggers, and, H. Rolly. 1969. Inhibition of release of vaccinia virus by N1-isonicotinoly-N2-3-methyl-4-chlorobenzoylhydrazine. J. Exp. Med.129:795808.
120. Kato, S. E.,, A. L. Strahl,, N. Moussatche, and, R. C. Condit. 2004. Temperature-sensitive mutants in the vaccinia virus 4b virion structural protein assemble malformed, transcriptionally inactive intracellular mature virions. Virology330:127146.
121. Katsafanas, G. C., and, B. Moss. 2004. Vaccinia virus intermediate stage transcription is complemented by Ras-GTPase-activating protein SH3 domain-binding protein (G3BP) and cytoplasmic activation/proliferation-associated protein (p137) individually or as a heterodimer. J. Biol. Chem.279:5221052217.
122. Keck, J. G.,, C. J. Baldick, Jr., and, B. Moss. 1990. Role of DNA replication in vaccinia virus gene expression: a naked template is required for transcription of three late trans-activator genes. Cell61:801809.
123. Keith, K. A.,, W. B. Wan,, S. L. Ciesla,, J. R. Beadle,, K. Y. Hostetler, and, E. R. Kern. 2004. Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro. Antimicrob. Agents Chemother.48:18691871.
124. Kern, E. R. 2003. In vitro activity of potential anti-poxvirus agents.Antivir. Res. 57:3540.
125. Kern, E. R.,, C. Hartline,, E. Harden,, K. Keith,, N. Rodriguez,, J. R. Beadle, and, K. Y. Hostetler. 2002. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother.46:991995.
126. Klemm, M.,, C. Cheng,, G. Cassell,, S. Shuman, and, A. M. Segall. 2000. Peptide inhibitors of DNA cleavage by tyrosine recombinases and topoisomerases. J. Mol. Biol.299:12031216.
127. Klemperer, N.,, W. McDonald,, K. Boyle,, B. Unger, and, P. Traktman. 2001. The A20R protein is a stoichiometric component of the processive form of vaccinia virus DNA polymerase. J. Virol.75:1229812307.
128. Klemperer, N.,, J. Ward,, E. Evans, and, P. Traktman. 1997. The vaccinia virus I1 protein is essential for the assembly of mature virions.J. Virol. 71:92859294.
129. Knutson, B. A.,, X. Liu,, J. Oh, and, S. S. Broyles. 2006. Vaccinia virus intermediate and late promoter elements are targeted by the TATA-binding protein. J. Virol.80:67846793.
130. Kornbluth, R. S.,, D. F. Smee,, R. W. Sidwell,, V. Snarsky,, D. H. Evans, and, K. Y. Hostetler. 2006. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype. Antimicrob. Agents Chemother.50:40384043.
131. Lackner, C. A., and, R. C. Condit. 2000. Vaccinia virus gene A18R DNA helicase is a transcript release factor. J. Biol. Chem.275:14851494.
132. Lackner, C. A.,, S. M. D’Costa,, C. Buck, and, R. C. Condit. 2003. Complementation analysis of the dales collection of vaccinia virus temperature-sensitive mutants. Virology305:240259.
133. Latner, D. R.,, J. M. Thompson,, P. D. Gershon,, C. Storrs, and, R. C. Condit. 2002. The positive transcription elongation factor activity of the vaccinia virus J3 protein is independent from its (nucleoside-2’-O-) methyltransferase and poly(A) polymerase stimulatory functions. Virology301:6480.
134. Latner, D. R.,, Y. Xiang,, J. I. Lewis,, J. Condit, and, R. C. Condit. 2000. The vaccinia virus bifunctional gene J3 (nucleoside-2’-O-)-methyltransferase and poly(A) polymerase stimulatory factor is implicated as a positive transcription elongation factor by two genetic approaches. Virology269:345355.
135. Law, M.,, G. C. Carter,, K. L. Roberts,, M. Hollinshead, and, G. L. Smith. 2006. Ligand-induced and nonfusogenic dissolution of a viral membrane. Proc. Natl. Acad. Sci. USA103:59895994.
136. Lawrence, S. J.,, K. R. Lottenbach,, F. K. Newman,, R. M. Buller,, C. J. Bellone,, J. J. Chen,, G. H. Cohen,, R. J. Eisenberg,, R. B. Belshe,, S. L. Stanley, Jr., and, S. E. Frey. 2007. Antibody responses to vaccinia membrane proteins after smallpox vaccination. J. Infect. Dis.196:220229.
137. LeDuc, J. W.,, I. Damon,, D. A. Relman,, J. Huggins, and, P. B. Jahrling. 2002. Smallpox research activities: U.S. interagency collaboration, 2001. Emerg. Infect. Dis.8:743745.
138. LeDuc, J. W., and, P. B. Jahrling. 2001. Strengthening national preparedness for smallpox: an update. Emerg. Infect. Dis.7:155157.
139. Lefkowitz, E. J.,, C. Upton,, S. S. Changayil,, C. Buck,, P. Traktman, and, R. M. Buller. 2005. Poxvirus Bioinformatics Resource Center: a comprehensive Poxviridae informational and analytical resource. Nucleic Acids Res.33:D311D316.
140. Li, G.,, N. Chen,, R. L. Roper,, Z. Feng,, A. Hunter,, M. Danila,, E. J. Lefkowitz,, R. M. Buller, and, C. Upton. 2005. Complete coding sequences of the rabbitpox virus genome. J. Gen. Virol.86:29692977.
141. Lin, S., and, S. S. Broyles. 1994. Vaccinia protein kinase 2: a second essential serine/threonine protein kinase encoded by vaccinia virus. Proc. Natl. Acad. Sci. USA91:76537657.
142. Lin, S.,, W. Chen, and, S. S. Broyles. 1992. The vaccinia virus B1R gene product is a serine/threonine protein kinase. J. Virol.66:27172723.
143. Liu, K.,, B. Lemon, and, P. Traktman. 1995. The dual-specificity phosphatase encoded by vaccinia virus, VH1, is essential for viral transcription in vivo and in vitro. J. Virol.69:78237834.
144. Magee, W. C.,, K. Y. Hostetler, and, D. H. Evans. 2005. Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob. Agents Chemother.49:31533162.
145. Mahr, A., and, B. E. Roberts. 1984. Organization of six early transcripts synthesized from a vaccinia virus EcoRI DNA fragment.J. Virol. 49:497509.
146. Mallardo, M.,, E. Leithe,, S. Schleich,, N. Roos,, L. Doglio, and, J. Krijnse Locker. 2002. Relationship between vaccinia virus intracellular cores, early mRNAs, and DNA replication sites. J. Virol.76:51675183.
147. Martin, S. A.,, E. Paoletti, and, B. Moss. 1975. Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions. J. Biol. Chem.250:93229329.
148. McDonald, W. F.,, N. Klemperer, and, P. Traktman. 1997. Characterization of a processive form of the vaccinia virus DNA polymerase. Virology 234:168175.
149. McDonald, W. F., and, P. Traktman. 1994. Vaccinia virus DNA polymerase. In vitro analysis of parameters affecting processivity. J. Biol. Chem.269:3119031197.
150. Meis, R. J., and, R. C. Condit. 1991. Genetic and molecular biological characterization of a vaccinia virus gene which renders the virus dependent on isatin-beta-thiosemicarbazone (IBT). Virology182:442454.
151. Meiser, A.,, C. Sancho, and, J. Krijnse Locker. 2003. Plasma membrane budding as an alternative release mechanism of the extracellular enveloped form of vaccinia virus from HeLa cells. J. Virol.77:99319942.
152. Mercer, J., and, P. Traktman. 2003. Investigation of structural and functional motifs within the vaccinia virus A14 phospho-protein, an essential component of the virion membrane. J. Virol.77:88578871.
153. Millns, A. K.,, M. S. Carpenter, and, A. M. DeLange. 1994. The vaccinia virus-encoded uracil DNA glycosylase has an essential role in viral DNA replication. Virology198:504513.
154. Miner, J. N., and, D. E. Hruby. 1989. Rifampicin prevents viro-some localization of L65, an essential vaccinia virus polypeptide. Virology170:227237.
155. Mohamed, M. R.,, D. R. Latner,, R. C. Condit, and, E. G. Niles. 2001. Interaction between the J3R subunit of vaccinia virus poly(A) polymerase and the H4L subunit of the viral RNA polymerase. Virology 280:143152.
156. Mohandas, A. R., and, S. Dales. 1995. Involvement of spicules in the formation of vaccinia virus envelopes elucidated by a conditional lethal mutant. Virology214:494502.
157. Moss, B. 2001. Poxviridae: the viruses and their replication, p. 3087. In B. N. Fields,, D. M. Knipe,, P. M. Howley, and, D. E. Griffin (ed.), Fields Virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
158. Moure, C. M.,, B. R. Bowman,, P. D. Gershon, and, F. A. Quiocho. 2006. Crystal structures of the vaccinia virus polyadenylate polymerase heterodimer: insights into ATP selectivity and processivity. Mol. Cell22:339349.
159. Moyer, R. W., and, R. L. Graves. 1981. The mechanism of cytoplasmic orthopoxvirus DNA replication. Cell27:391401.
160. Munyon, W.,, E. Paoletti, and, J. T. Grace, Jr. 1967. RNA polymerase activity in purified infectious vaccinia virus. Proc. Natl. Acad. Sci. USA58:22802287.
161. Myskiw, C.,, Y. Deschambault,, K. Jefferies,, R. He, and, J. Cao. 2007. Aurintricarboxylic acid inhibits the early stage of vaccinia virus replication by targeting both cellular and viral factors. J. Virol.81:30273032.
162. Naesens, L.,, R. Snoeck,, G. Andrei,, J. Balzarini,, J. Neyts, and, E. De Clercq. 1997. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antivir. Chem. Chemother.8:123.
163. Nettleton, P. F.,, J. A. Gilray,, H. W. Reid, and, A. A. Mercer. 2000. Parapoxviruses are strongly inhibited in vitro by cidofovir. Anti-vir. Res.48:205208.
164. Newsome, T. P.,, N. Scaplehorn, and, M. Way. 2004. SRC mediates a switch from microtubule- to actin-based motility of vaccinia virus. Science306:124129.
165. Neyts, J., and, E. De Clercq. 2001. Efficacy of 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine for treatment of vaccinia virus (orthopoxvirus) infections in mice. Antimicrob. Agents Chemother.45:8487.
166. Neyts, J., and, E. De Clercq. 1993. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J. Med. Virol.41:242246.
167. Neyts, J.,, E. Verbeken, and, E. De Clercq. 2002. Effect of 5-iodo-2’-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice.Antimicrob. Agents Chemother. 46:28422847.
168. Nichols, R. J.,, M. S. Wiebe, and, P. Traktman. 2006. The vaccinia-related kinases phosphorylate the N’ terminus of BAF, regulating its interaction with DNA and its retention in the nucleus. Mol.Biol. Cell17:24512464.
169. Niles, E. G.,, G. J. Lee-Chen,, S. Shuman,, B. Moss, and, S. S. Broyles. 1989. Vaccinia virus gene D12L encodes the small subunit of the viral mRNA capping enzyme. Virology172:513522.
170. Noble, M. E.,, J. A. Endicott, and, L. N. Johnson. 2004. Protein kinase inhibitors: insights into drug design from structure. Science303:18001805.
171. Oh, J., and, S. S. Broyles. 2005. Host cell nuclear proteins are recruited to cytoplasmic vaccinia virus replication complexes. J. Virol.79:1285212860.
172. Ojeda, S.,, T. G. Senkevich, and, B. Moss. 2006. Entry of vaccinia virus and cell-cell fusion require a highly conserved cysteine-rich membrane protein encoded by the A16L gene. J. Virol. 80:5161.
173. O’Toole, T. 1999. Smallpox: an attack scenario. Emerg. Infect. Dis.5:540546.
174. Painter, G. R.,, L. C. Trost,, B. L. Lambert,, M. R. Almond,, M. Buller,, E. R. Kern,, G. P. Painter,, A. T. Robertson, and, R. O’Mahony. 2008. CMX001. Anti-smallpox agent, anti-cytomegalovirus agent, viral polymerase inhibitor. Drugs Future. 33:655661.
175. Parker, S.,, E. Touchette,, C. Oberle,, M. Almond,, A. Robertson,, L. C. Trost,, B. Lampert,, G. Painter, and, R. M. Buller. 2008. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antivir.Res.77:3949.
176. Parrish, S.,, W. Resch, and, B. Moss. 2007. Vaccinia virus D10 protein has mRNA decapping activity, providing a mechanism for control of host and viral gene expression. Proc. Natl. Acad.Sci. USA104:21392144.
177. Payne, L. G., and, K. Kristensson. 1985. Extracellular release of enveloped vaccinia virus from mouse nasal epithelial cells in vivo.J. Gen. Virol. 66 (Pt. 3):643646.
178. Pedersen, K.,, E. J. Snijder,, S. Schleich,, N. Roos,, G. Griffiths, and, J. K. Locker. 2000. Characterization of vaccinia virus intracellular cores: implications for viral uncoating and core structure. J. Virol.74:35253536.
179. Pedley, C. B., and, R. J. Cooper. 1987. The assay, purification and properties of vaccinia virus-induced uncoating protein. J. Gen. Virol.68 (Pt. 4):10211028.
180. Pennington, H. 2003. Smallpox and bioterrorism. Bull. W. H. O. 81:762767.
181. Perdiguero, B., and, R. Blasco. 2006. Interaction between vaccinia virus extracellular virus envelope A33 and B5 glycoproteins.J. Virol. 80:87638777.
182. Prichard, M. N.,, K. A. Keith,, M. P. Johnson,, E. A. Harden,, A. McBrayer,, M. Luo,, S. Qiu,, D. Chattopadhyay,, X. Fan,, P. F. Torrence, and, E. R. Kern. 2007. Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase. Antimicrob. Agents Chemother.51:17951803.
183. Prichard, M. N.,, K. A. Keith,, D. C. Quenelle, and, E. R. Kern. 2006. Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections. Anti-microb. Agents Chemother.50:13361341.
184. Prichard, M. N., and, E. R. Kern. 2005. Orthopoxvirus targets for the development of antiviral therapies. Curr. Drug Targets Infect. Disord.5:1728.
185. Punjabi, A., and, P. Traktman. 2005. Cell biological and functional characterization of the vaccinia virus F10 kinase: implications for the mechanism of virion morphogenesis. J. Virol.79:21712190.
186. Quenelle, D. C.,, R. M. Buller,, S. Parker,, K. A. Keith,, D. E. Hruby,, R. Jordan, and, E. R. Kern. 2007. Efficacy of delayed treatment with ST-246 given orally against systemic orthopox-virus infections in mice. Antimicrob. Agents Chemother. 51:689695.
187. Quenelle, D. C.,, D. J. Collins, and, E. R. Kern. 2004. Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir. Antivir. Res.63:3340.
188. Quenelle, D. C.,, D. J. Collins, and, E. R. Kern. 2003. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob. Agents Chemother.47:32753280.
189. Quenelle, D. C.,, D. J. Collins,, W. B. Wan,, J. R. Beadle,, K. Y. Hostetler, and, E. R. Kern. 2004. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother.48:404412.
190. Quenelle, D. C.,, K. A. Keith, and, E. R. Kern. 2006. In vitro and in vivo evaluation of isatin-beta-thiosemicarbazone and marboran against vaccinia and cowpox virus infections. Antivir. Res.71:2430.
191. Quenelle, D. C.,, M. N. Prichard,, K. A. Keith,, D. E. Hruby,, R. Jordan,, G. R. Painter,, A. Robertson, and, E. R. Kern. 2007. Synergistic efficacy of the combination ST-246 with CMX001 against orthopoxviruses. Antimicrob. Agents Chemother. 51:41184124.
192. Rajagopal, I.,, B. Y. Ahn,, B. Moss, and, C. K. Mathews. 1995. Roles of vaccinia virus ribonucleotide reductase and glutaredoxin in DNA precursor biosynthesis. J. Biol. Chem. 270:2741527418.
193. Reed, K. D.,, J. W. Melski,, M. B. Graham,, R. L. Regnery,, M. J. Sotir,, M. V. Wegner,, J. J. Kazmierczak,, E. J. Stratman,, Y. Li,, J. A. Fairley,, G. R. Swain,, V. A. Olson,, E. K. Sargent,, S. C. Kehl,, M. A. Frace,, R. Kline,, S. L. Foldy,, J. P. Davis, and, I. K. Damon. 2004. The detection of monkeypox in humans in the Western Hemisphere.N. Engl. J. Med. 350:342350.
194. Reeves, P. M.,, B. Bommarius,, S. Lebeis,, S. McNulty,, J. Christensen,, A. Swimm,, A. Chahroudi,, R. Chavan,, M. B. Feinberg,, D. Veach,, W. Bornmann,, M. Sherman, and, D. Kalman. 2005. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat. Med.11:731739.
195. Rempel, R. E., and, P. Traktman. 1992. Vaccinia virus B1 kinase: phenotypic analysis of temperature-sensitive mutants and enzymatic characterization of recombinant proteins. J. Virol. 66:44134426.
196. Resch, W.,, A. S. Weisberg, and, B. Moss. 2005. Vaccinia virus nonstructural protein encoded by the A11R gene is required for formation of the virion membrane. J. Virol.79:65986609.
197. Richter, S.,, C. Parolin,, M. Palumbo, and, G. Palu. 2004. Antiviral properties of quinolone-based drugs. Curr. Drug Targets Infect. Disord.4:111116.
198. Risco, C.,, J. R. Rodriguez,, W. Demkowicz,, R. Heljasvaara,, J. L. Carrascosa,, M. Esteban, and, D. Rodriguez. 1999. The vaccinia virus 39-kDa protein forms a stable complex with the p4a/4a major core protein early in morphogenesis. Virology265:375386.
199. Rochester, S. C., and, P. Traktman. 1998. Characterization of the single-stranded DNA binding protein encoded by the vaccinia virus I3 gene. J. Virol.72:29172926.
200. Rodriguez, D.,, M. Barcena,, W. Mobius,, S. Schleich,, M. Esteban,, W. J. Geerts,, A. J. Koster,, G. Griffiths, and, J. K. Locker. 2006. A vaccinia virus lacking A10L: viral core proteins accumulate on structures derived from the endoplasmic reticulum. Cell. Micro-biol.8:427437.
201. Roper, R. L., and, B. Moss. 1999. Envelope formation is blocked by mutation of a sequence related to the HKD phospholipid metabolism motif in the vaccinia virus F13L protein. J. Virol.73:11081117.
202. Roper, R. L.,, L. G. Payne, and, B. Moss. 1996. Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene. J. Virol.70:37533762.
203. Rosel, J. L.,, P. L. Earl,, J. P. Weir, and, B. Moss. 1986. Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the HindIII H genome fragment. J. Virol.60:436449.
204. Safrin, S.,, J. Cherrington, and, H. S. Jaffe. 1997. Clinical uses of cidofovir. Rev. Med. Virol.7:145156.
205. Sagot, J., and, G. Beaud. 1979. Phosphorylation in vivo of a vaccinia-virus structural protein found associated with the ribosomes from infected cells. Eur. J. Biochem.98:131140.
206. Sanderson, C. M.,, M. Hollinshead, and, G. L. Smith. 2000. The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles. J. Gen. Virol.81:4758.
207. Santos, C. R.,, S. Blanco,, A. Sevilla, and, P. A. Lazo. 2006. Vaccinia virus B1R kinase interacts with JIP1 and modulates c-Jun-dependent signaling. J. Virol.80:76677675.
208. Santos, C. R.,, F. M. Vega,, S. Blanco,, R. Barcia, and, P. A. Lazo. 2004. The vaccinia virus B1R kinase induces p53 downregulation by an Mdm2-dependent mechanism. Virology328:254265.
209. Sauerbrei, A.,, C. Meier,, A. Meerbach,, M. Schiel,, B. Helbig, and, P. Wutzler. 2005. In vitro activity of cycloSal-nucleoside mono-phosphates and polyhydroxycarboxylates against orthopoxviruses.Antivir. Res. 67:147154.
210. Sauerbrei, A.,, C. Meier,, A. Meerbach, and, P. Wutzler. 2006. Inhibitory efficacy of cyclosal-nucleoside monophosphates of aciclovir and brivudin on DNA synthesis of orthopoxviruses. Anti-vir. Chem. Chemother.17:2531.
211. Schmutz, C.,, L. G. Payne,, J. Gubser, and, R. Wittek. 1991. A mutation in the gene encoding the vaccinia virus 37,000-M(r) protein confers resistance to an inhibitor of virus envelopment and release. J. Virol.65:34353442.
212. Schwer, B., and, S. Shuman. 2006. Genetic analysis of poxvirus mRNA cap methyltransferase: suppression of conditional mutations in the stimulatory D12 subunit by second-site mutations in the catalytic D1 subunit. Virology352:145156.
213. Sekiguchi, J., and, S. Shuman. 1997. Nick sensing by vaccinia virus DNA ligase requires a 5’ phosphate at the nick and occupancy of the adenylate binding site on the enzyme. J. Virol.71:96799684.
214. Sekiguchi, J., and, S. Shuman. 1997. Novobiocin inhibits vaccinia virus replication by blocking virus assembly. Virology 235:129137.
215. Senkevich, T. G.,, S. Ojeda,, A. Townsley,, G. E. Nelson, and, B. Moss. 2005. Poxvirus multiprotein entry-fusion complex. Proc. Natl. Acad. Sci. USA102:1857218577.
216. Senkevich, T. G.,, C. L. White,, E. V. Koonin, and, B. Moss. 2002. Complete pathway for protein disulfide bond formation encoded by poxviruses. Proc. Natl. Acad. Sci. USA99:66676672.
217. Shaffer, R., and, P. Traktman. 1987. Vaccinia virus encapsidates a novel topoisomerase with the properties of a eucaryotic type I enzyme.J. Biol. Chem. 262:93099315.
218. Shuman, S. 1990. Catalytic activity of vaccinia mRNA capping enzyme subunits coexpressed in Escherichia coli. J. Biol. Chem.265:1196011966.
219. Shuman, S.,, S. S. Broyles, and, B. Moss. 1987. Purification and characterization of a transcription termination factor from vaccinia virions. J. Biol. Chem.262:1237212380.
220. Shuman, S., and, B. Moss. 1988. Factor-dependent transcription termination by vaccinia virus RNA polymerase. Evidence that the cis-acting termination signal is in nascent RNA. J. Biol. Chem.263:62206225.
221. Sidwell, R. W.,, J. H. Huffman,, G. P. Khare,, L. B. Allen,, J. T. Witkowski, and, R. K. Robins. 1972. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.Science 177:705706.
222. Simpson, D. A., and, R. C. Condit. 1995. Vaccinia virus gene A18R encodes an essential DNA helicase. J. Virol. 69:61316139.
223. Slabaugh, M. B.,, T. L. Johnson, and, C. K. Mathews. 1984. Vaccinia virus induces ribonucleotide reductase in primate cells. J. Virol.52:507514.
224. Slabaugh, M. B., and, C. K. Mathews. 1986. Hydroxyurea-resistant vaccinia virus: overproduction of ribonucleotide reductase.J. Virol. 60:506514.
225. Smee, D. F.,, K. W. Bailey,, M. Wong, and, R. W. Sidwell. 2000. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. Antivir. Res.47:171177.
226. Smee, D. F.,, M. Bray, and, J. W. Huggins. 2001. Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro. Antivir. Chem. Chemother.12:327335.
227. Smee, D. F.,, B. L. Hurst,, M. H. Wong,, R. I. Glazer,, A. Rahman, and, R. W. Sidwell. 2007. Efficacy of N-methanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of vaccinia virus. Antivir. Res.76:124129.
228. Smee, D. F.,, R. W. Sidwell,, D. Kefauver,, M. Bray, and, J. W. Huggins. 2002. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob. Agents Chemother.46:13291335.
229. Smee, D. F.,, M. K. Wandersee,, K. W. Bailey,, M. H. Wong,, C. K. Chu,, S. Gadthula, and, R. W. Sidwell. 2007. Cell line dependency for antiviral activity and in vivo efficacy of N-methanocarbathymidine against orthopoxvirus infections in mice. Antivir. Res.73:6977.
230. Smee, D. F.,, M. H. Wong,, K. W. Bailey,, J. R. Beadle,, K. Y. Hostetler, and, R. W. Sidwell. 2004. Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice. Int. J. Antimicrob. Agents23:430437.
231. Smith, G. L., and, M. Law. 2004. The exit of vaccinia virus from infected cells. Virus Res.106:189197.
232. Smith, G. L.,, A. Vanderplasschen, and, M. Law. 2002. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol.83:29152931.
233. Sodeik, B.,, R. W. Doms,, M. Ericsson,, G. Hiller,, C. E. Machamer,, W. van ’t Hof,, G. van Meer,, B. Moss, and, G. Griffiths. 1993. Assembly of vaccinia virus: role of the intermediate compartment between the endoplasmic reticulum and the Golgi stacks. J. Cell Biol.121:521541.
234. Stanitsa, E. S.,, L. Arps, and, P. Traktman. 2006. Vaccinia virus uracil DNA glycosylase interacts with the A20 protein to form a heterodimeric processivity factor for the viral DNA polymerase. J. Biol. Chem.281:34393451.
235. Stuart, D.,, K. Ellison,, K. Graham, and, G. McFadden. 1992. In vitro resolution of poxvirus replicative intermediates into linear minichromosomes with hairpin termini by a virally induced Holliday junction endonuclease. J. Virol.66:15511563.
236. Stuart, D. T.,, C. Upton,, M. A. Higman,, E. G. Niles, and, G. McFadden. 1993. A poxvirus-encoded uracil DNA glycosylase is essential for virus viability. J. Virol.67:25032512.
237. Szajner, P.,, H. Jaffe,, A. S. Weisberg, and, B. Moss. 2004. A complex of seven vaccinia virus proteins conserved in all chordopox-viruses is required for the association of membranes and viroplasm to form immature virions. Virology330:447459.
238. Szajner, P.,, H. Jaffe,, A. S. Weisberg, and, B. Moss. 2003. Vaccinia virus G7L protein interacts with the A30L protein and is required for association of viral membranes with dense viroplasm to form immature virions. J. Virol.77:34183429.
239. Szajner, P.,, A. S. Weisberg,, J. Lebowitz,, J. Heuser, and, B. Moss. 2005. External scaffold of spherical immature poxvirus particles is made of protein trimers, forming a honeycomb lattice. J. Cell Biol.170:971981.
240. Szajner, P.,, A. S. Weisberg, and, B. Moss. 2004. Evidence for an essential catalytic role of the F10 protein kinase in vaccinia virus morphogenesis.J. Virol. 78:257265.
241. Taddie, J. A., and, P. Traktman. 1993. Genetic characterization of the vaccinia virus DNA polymerase: cytosine arabinoside resistance requires a variable lesion conferring phosphonoacetate resistance in conjunction with an invariant mutation localized to the 3’-5’ exonuclease domain. J. Virol.67:43234336.
242. Taddie, J. A., and, P. Traktman. 1991. Genetic characterization of the vaccinia virus DNA polymerase: identification of point mutations conferring altered drug sensitivities and reduced fidelity. J. Virol.65:869879.
243. Tartaglia, J.,, M. E. Perkus,, J. Taylor,, E. K. Norton,, J. C. Audonnet,, W. I. Cox,, S. W. Davis,, J. van der Hoeven,, B. Meignier,, M. Riviere, et al. 1992. NYVAC: a highly attenuated strain of vaccinia virus. Virology188:217232.
244. Tian, L., and, S. Shuman. 2007. Vaccinia topoisomerase mutants illuminate roles for Phe59, Gly73, Gln69 and Phe215. Virology359:466476.
245. Tolonen, N.,, L. Doglio,, S. Schleich, and, J. Krijnse Locker. 2001. Vaccinia virus DNA replication occurs in endoplasmic reticulum-enclosed cytoplasmic mini-nuclei. Mol. Biol. Cell 12:20312046.
246. Topalis, D.,, B. Collinet,, C. Gasse,, L. Dugue,, J. Balzarini,, S. Pochet, and, D. Deville-Bonne. 2005. Substrate specificity of vaccinia virus thymidylate kinase. FEBS J.272:62546265.
247. Traktman, P.,, M. K. Anderson, and, R. E. Rempel. 1989. Vaccinia virus encodes an essential gene with strong homology to protein kinases. J. Biol. Chem.264:2145821461.
248. Traktman, P., and, K. Boyle. 2004. Methods for analysis of pox-virus DNA replication. Methods Mol. Biol.269:169186.
249. Traktman, P.,, A. Caligiuri,, S. A. Jesty,, K. Liu, and, U. Sankar. 1995. Temperature-sensitive mutants with lesions in the vaccinia virus F10 kinase undergo arrest at the earliest stage of virion morphogenesis.J. Virol. 69:65816587.
250. Traktman, P.,, P. Sridhar,, R. C. Condit, and, B. E. Roberts. 1984. Transcriptional mapping of the DNA polymerase gene of vaccinia virus. J. Virol.49:125131.
251. Turner, P. C., and, R. W. Moyer. 2002. Poxvirus immune modulators: functional insights from animal models. Virus Res. 88:3553.
252. Underwood, M. R.,, R. J. Harvey,, S. C. Stanat,, M. L. Hemphill,, T. Miller,, J. C. Drach,, L. B. Townsend, and, K. K. Biron.1998. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J. Virol.72:717725.
253. Unger, B., and, P. Traktman. 2004. Vaccinia virus morphogenesis: a13 phosphoprotein is required for assembly of mature virions.J. Virol. 78:88858901.
254. Upton, C.,, S. Slack,, A. L. Hunter,, A. Ehlers, and, R. L. Roper. 2003. Poxvirus orthologous clusters: toward defining the minimum essential poxvirus genome. J. Virol.77:75907600.
255. Upton, C.,, D. T. Stuart, and, G. McFadden. 1993. Identification of a poxvirus gene encoding a uracil DNA glycosylase. Proc. Natl. Acad. Sci. USA90:45184522.
256. van Eijl, H.,, M. Hollinshead,, G. Rodger,, W. H. Zhang, and, G. L. Smith. 2002. The vaccinia virus F12L protein is associated with intracellular enveloped virus particles and is required for their egress to the cell surface. J. Gen. Virol.83:195207.
257. van Eijl, H.,, M. Hollinshead, and, G. L. Smith. 2000. The vaccinia virus A36R protein is a type Ib membrane protein present on intracellular but not extracellular enveloped virus particles. Virology271:2636.
258. Venkatesan, S.,, A. Gershowitz, and, B. Moss. 1980. Modification of the 5’ end of mRNA. Association of RNA triphosphatase with the RNA guanylyltransferase-RNA (guanine-7-)methyltransferase complex from vaccinia virus. J. Biol. Chem.255:903908.
259. Wang, S., and, S. Shuman. 1995. Vaccinia virus morphogenesis is blocked by temperature-sensitive mutations in the F10 gene, which encodes protein kinase 2. J. Virol.69:63766388.
260. Ward,, B. M. 2005. Visualization and characterization of the intracellular movement of vaccinia virus intracellular mature virions.J. Virol. 79:47554763.
261. Ward, B. M., and, B. Moss. 2000. Golgi network targeting and plasma membrane internalization signals in vaccinia virus B5R envelope protein. J. Virol.74:37713780.
262. Ward, B. M., and, B. Moss. 2001. Vaccinia virus intracellular movement is associated with microtubules and independent of actin tails. J. Virol.75:1165111663.
263. Ward, B. M.,, A. S. Weisberg, and, B. Moss. 2003. Mapping and functional analysis of interaction sites within the cytoplasmic domains of the vaccinia virus A33R and A36R envelope proteins.J. Virol. 77:41134126.
264. Webb, T. J.,, R. A. Litavecz,, M. A. Khan,, W. Du,, J. Gervay-Hague,, G. J. Renukaradhya, and, R. R. Brutkiewicz. 2006. Inhibition of CD1d1-mediated antigen presentation by the vaccinia virus B1R and H5R molecules. Eur. J. Immunol.36:25952600.
265. Wolffe, E. J.,, S. N. Isaacs, and, B. Moss. 1993. Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination.J. Virol. 67:47324741.
266. Wolffe, E. J.,, E. Katz,, A. Weisberg, and, B. Moss. 1997. The A34R glycoprotein gene is required for induction of specialized actin-containing microvilli and efficient cell-to-cell transmission of vaccinia virus. J. Virol.71:39043915.
267. Wolffe, E. J.,, S. Vijaya, and, B. Moss. 1995. A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology211:5363.
268. Woodson, B., and, W. K. Joklik. 1965. The inhibition of vaccinia virus multiplication by isatin-beta-thiosemicarbazone. Proc. Natl. Acad. Sci. USA54:946953.
269. Wright, C. F.,, B. W. Oswald, and, S. Dellis. 2001. Vaccinia virus late transcription is activated in vitro by cellular heterogeneous nuclear ribonucleoproteins. J. Biol. Chem.276:4068040686.
270. Yakovleva, L.,, C. J. Handy,, J. M. Sayer,, M. Pirrung,, D. M. Jerina, and, S. Shuman. 2004. Benzo(c)phenanthrene adducts and nogalamycin inhibit DNA transesterification by vaccinia topoisomerase.J. Biol. Chem.279:2333523342.
271. Yang, G.,, D. C. Pevear,, M. H. Davies,, M. S. Collett,, T. Bailey,, S. Rippen,, L. Barone,, C. Burns,, G. Rhodes,, S. Tohan,, J. W. Huggins,, R. O. Baker,, R. L. Buller,, E. Touchette,, K. Waller,, J. Schriewer,, J. Neyts,, E. DeClercq,, K. Jones,, D. Hruby, and, R. Jordan. 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79:1313913149.
272. Yoder, J. D.,, T. S. Chen,, C. R. Gagnier,, S. Vemulapalli,, C. S. Maier, and, D. E. Hruby. 2006. Pox proteomics: mass spectrometry analysis and identification of Vaccinia virion proteins. Virol. J.3:10.